Ribotyping differentiates relapse from reinfection in the treatment failures of Escherichia coli urinary tract infections in children.
Analysis of restriction fragment-length polymorphism of ribosomal DNA regions (ribotypes) was used as an epidemiologic tool to compare 25 pre- and posttreatment strains obtained from 12 patients treated with either cefpodoxime proxetil or amoxicillin-clavulanic acid. Ribotyping is a promising method to differentiate relapse from reinfection in the treatment failures of Escherichia coli urinary tract infections.
Bingen
E
E
Division of Microbiology, Robert Debré Hospital, Paris, France.
Rangaraj
M
M
Safran
C
C
D000658:Amoxicillin / Q000627:therapeutic use; D015296:Ceftizoxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use; D004275:DNA, Ribosomal; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004926:Escherichia coli / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007223:Infant; D012008:Recurrence; D017211:Treatment Failure; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D000097627:Cefpodoxime Proxetil
D000658:Amoxicillin; D015296:Ceftizoxime; D019818:Clavulanic Acid; D002969:Clavulanic Acids; D004275:DNA, Ribosomal; D000097627:Cefpodoxime Proxetil